PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28232617-3	2017	Bortezomib treatment given intravenously twice weekly for 1 month (1.3 mg/m2 per dose) clearly reduced the numbers of antibody-producing cells and CD38+CD19+CD20- plasma cells in the bone marrow (P<0.05), but donor-specific alloantibody levels did not decrease.	Bortezomib	0-10	keratin 20	Homo sapiens	157-161	
32685310-5	2020	This case report is about a patient with a history of advanced acquired immunodeficiency syndrome (AIDS) with a cluster of differentiation 4 (CD4) count <20 who had CD20 negative plasmablastic lymphoma and was successfully treated with the combination of bortezomib and dose-adjusted EPOCH (V-EPOCH) and intrathecal chemotherapy, achieving complete response with optimal tolerance.	Bortezomib	255-265	keratin 20	Homo sapiens	165-169	
27980307-4	2016	Furthermore, some targeting drugs, such as lenalidomide, bortezomib and ibrutinib, directly or indirectly affect CD20 protein expression.	Bortezomib	57-67	keratin 20	Homo sapiens	113-117	
28367758-4	2017	In the face of persistent proteinuria despite combined conservative rituximab therapy over several months and the total eradication of CD20-positive cells, bortezomib was introduced.	Bortezomib	156-166	keratin 20	Homo sapiens	135-139	
23927993-8	2013	Among patients receiving bortezomib-based treatment, patients harboring t(11;14) without CD20 expression had a significantly shortened PFS (11.0 versus 43.0 months, p=0.005) and OS (16.5 versus 54.0 months, p=0.016) compared with patients displaying t(11;14) with CD20.	Bortezomib	25-35	keratin 20	Homo sapiens	89-93	
24528507-0	2014	CD20-positive plasmablastic lymphoma with excellent response to bortezomib combined with rituximab.	Bortezomib	64-74	keratin 20	Homo sapiens	0-4	
23927993-8	2013	Among patients receiving bortezomib-based treatment, patients harboring t(11;14) without CD20 expression had a significantly shortened PFS (11.0 versus 43.0 months, p=0.005) and OS (16.5 versus 54.0 months, p=0.016) compared with patients displaying t(11;14) with CD20.	Bortezomib	25-35	keratin 20	Homo sapiens	264-268	
20200358-0	2010	Bortezomib modulates surface CD20 in B-cell malignancies and affects rituximab-mediated complement-dependent cytotoxicity.	Bortezomib	0-10	keratin 20	Homo sapiens	29-33	
20200358-6	2010	Short-term (24 hours) incubation of Raji cells with 10 or 20 nM bortezomib did not change surface CD20 levels, but sensitized CD20(+) lymphoma cells to R-CDC.	Bortezomib	64-74	keratin 20	Homo sapiens	126-130	
20200358-7	2010	Prolonged (48 hours) incubation with 20 nM bortezomib, or incubation with 50 nM bortezomib for 24 hours led to a significant decrease in surface CD20 levels as well as R-CDC.	Bortezomib	43-53	keratin 20	Homo sapiens	145-149	
20200358-7	2010	Prolonged (48 hours) incubation with 20 nM bortezomib, or incubation with 50 nM bortezomib for 24 hours led to a significant decrease in surface CD20 levels as well as R-CDC.	Bortezomib	80-90	keratin 20	Homo sapiens	145-149	
23305345-0	2013	Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors.	Bortezomib	11-21	keratin 20	Homo sapiens	58-62	
23305345-6	2013	CONCLUSIONS: These results demonstrate that acquired resistance to BTZ in B cells can be overcome by next generation PIs and by anti-CD20/rituximab-induced CDC, thereby paving the way for salvage therapy in BTZ-resistant disease.	Bortezomib	67-70	keratin 20	Homo sapiens	133-137	
23305345-6	2013	CONCLUSIONS: These results demonstrate that acquired resistance to BTZ in B cells can be overcome by next generation PIs and by anti-CD20/rituximab-induced CDC, thereby paving the way for salvage therapy in BTZ-resistant disease.	Bortezomib	207-210	keratin 20	Homo sapiens	133-137	
20574159-2	2010	Therefore, proteasome inhibitors including the clinically approved bortezomib might influence the levels of CD20, a rituximab target antigen.	Bortezomib	67-77	keratin 20	Homo sapiens	108-112	
34461632-6	2021	Given bortezomib"s activity in relapsed ALL and its synergism with rituximab in B-cell lymphomas, the addition of bortezomib to rituximab and chemotherapy may provide an incremental benefit in CD20-positive-precursor B-cell ALL.	Bortezomib	114-124	keratin 20	Homo sapiens	193-197